iBio (NYSE AMERICAN:IBIO) appointed Dr. Linda Armstrong, a renowned biopharma executive, as a director and a member of the board’s new science and technology committee.
“We are pleased to welcome Dr. Armstrong to our board and are confident that her deep experience in the development and registration of biologics will be an asset to iBio,” Tom Isett, iBio’s chairman and CEO, said in a statement.
“Moreover, as an expert pulmonologist, we believe her guidance will be critical as we progress the development of our respiratory disease portfolio, which includes COVID-19 vaccine and therapeutic candidates, as well as IBIO-100, which includes idiopathic pulmonary fibrosis as a potential indication,” he added.
Dr. Armstrong is a board-certified pulmonologist and internist with more than 20 years of experience in respiratory diseases and therapeutics. She is the global head of the respiratory development unit at Novartis (SWX:NOVN), responsible for the development of therapies to treat patients with respiratory and allergic conditions.
